Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Reece
Donna E
DE
Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada. donna.reece@uhn.on.ca
Sullivan
Dan
D
Lonial
Sagar
S
Mohrbacher
Ann F
AF
Chatta
Gurkamal
G
Shustik
Chaim
C
Burris
Howard
H
Venkatakrishnan
Karthik
K
Neuwirth
Rachel
R
Riordan
William J
WJ
Karol
Michael
M
von Moltke
Lisa L
LL
Acharya
Milin
M
Zannikos
Peter
P
Keith Stewart
A
A
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001897:Boronic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000069286:Bortezomib; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D012008:Recurrence; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib